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Clinical Infectious Diseases
C O R R E S P O N D E N C E
CORRESPONDENCE • cid 2019:XX (XX XXXX) • 1
Respiratory Syncytial Virus 
Infection Morbidity in the 
Elderly: Time for Repurposing of 
Ribavirin?
To the Editor—We have read with great 
interest the report by Ackerson et al [1] 
on the morbidity and mortality rates as-
sociated with respiratory syncytial virus 
(RSV) compared with influenza virus in-
fections in older adults. They conclude 
that RSV may result in higher morbidity 
and mortality rates among older hospital-
ized adults than influenza virus.
These results are an important step in 
recognizing the impact of RSV across the 
whole patient population. Historically, 
the most attention has been paid to RSV 
infections in infants and in the moder-
ately to severely immunocompromised 
and less to infection in the population 
described by Ackerson et al [1], namely, 
adults >60 years old. Unlike previous re-
ports comparing hospitalization in RSV 
and influenza virus infections, the authors 
found a higher incidence of hospitaliza-
tions lasting ≥7  days in the RSV cohort 
than in the influenza virus cohort, which 
they suggest may reflect the increased 
use in recent years of antivirals directed 
at influenza virus, but not RSV. They re-
ported that 47.1% of RSV-infected and 
78.6% of influenza virus–infected indi-
viduals received antiviral therapy during 
the hospitalization period; 99% received 
oseltamivir, even though oseltamivir has 
no activity against RSV [2]. 
Inhaled ribavirin and palivizumab are 
currently the only registered treatment 
options for RSV in addition to supportive 
care; however, inhaled ribavirin is rarely 
used in nonimmunocompromised adults 
because of the limited evidence for its 
efficacy, its price, and the occupational 
risk to healthcare workers exposed of 
ribavirin aerosols [2, 3]. Vaccines and 
new antivirals are being tested, but they 
are not yet available for daily practice. 
The aging population, however, may ben-
efit from using oral ribavirin, which has 
been described in the setting of hemato-
poietic stem cell and lung transplantation 
[4]. Although evidence from random-
ized controlled trials is lacking, ribavirin 
treatment may have a beneficial effect in 
reducing morbidity and mortality rates 
or improving recovery of pulmonary 
function after RSV infection in transplant 
recipients [5–7]. As shown elsewhere, 
oral ribavirin may not be inferior to in-
haled therapy in this population and may 
provide a good and affordable treatment 
option [8, 9]. Whether these data can 
also be applied to the population of older 
adults remains to be confirmed.
The absence of evidence for the effi-
cacy of oral ribavirin in elderly persons, 
combined with the widespread incidence 
and detrimental effects of RSV infection 
in this population, shown by Ackerson 
et  al and others [1, 10], underlines the 
need for a well-designed randomized 
controlled trial to determine the benefit 
of a short course of oral ribavirin for RSV 
in elderly patients, analogous to the cur-
rent use of oseltamivir for influenza virus. 
This is especially important in the light 
of upcoming (and probably expensive) 
new antivirals, for which ribavirin could 
be considered as an active comparator. 
Furthermore, considering the high inci-
dence and availability of quick diagnostic 
methods for RSV, we deem such a study 
not only needed but also certainly feasible. 
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